Clozapine study for people with a specific schizophrenia or bipolar type
Treatments studied
Part of Mental health clinical trials.
This trial tests whether clozapine works better for people whose illness fits a specific “biotype-1” pattern. It may help reduce ongoing symptoms, but it also requires close safety monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 60, and can sign written consent
- You have schizophrenia, schizoaffective disorder, or bipolar I disorder with psychosis
- Your symptom severity scores are high enough (PANSS total 70 or higher)
- Your regular blood test for infection-fighting cells is normal (ANC above 1500)
- You can speak/read English and are medically stable enough for study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of a daily medication (olanzapine-samidorphan) and a structured exercise program can help people with schizophrenia, schizoaffective disorder, or bipolar disorder improve their health and well-being.
This study looks at “biomarkers,” or blood measures, in people with schizophrenia who respond to clozapine. It may help researchers understand who benefits from clozapine and why, by linking test results to symptom changes.
This trial tests whether clozapine can reduce repeat violent behavior in people with schizophrenia or schizoaffective disorder. Participants are randomly assigned to clozapine or usual care to see which approach works better for preventing violence.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.